As of November 2013
Research Education Updates
The PI3K signaling pathway regulates cell survival, proliferation, and growth. Learn more about the potential benefits of PI3K pathway inhibitors and their role in advancing cancer therapy.
As of August 2013
Pipeline Molecules Updates
PI3K-alpha Inhibitor (GDC-0032)
Learn more about how GDC-0032 may affect tumor cell growth and regression by inhibiting PI3Kα
As of May 2013
Research Education Updates:
Research Cancer Immunotherapy
Learn more about the potential of PD-L1 inhibition and cancer immunotherapy.
Updated the site to include more information about Glycoengineering.
Pipeline Molecules Updates:
Pipeline Overview: Content Update
For more information about molecules in early-and late stage development download the new brochure.
Anti-PDL1 targets, a protein expressed on the surface of cancer cells. Find out how this molecule was designed to help promote anti-tumor immune activity.
Anti-CD22 ADC (DCDT2980S)
The Anti-CD22 ADC is composed of a MAb, a stable linker, and a cytotoxic. Find out how this molecule may selectively target B-cells expressing CD22.
Anti-CD79b ADC (DCDS4501A)
The Anti-CD79b ADC is composed of a MAb, a stable linker, and a cytotoxic. Find out how this molecule may selectively bind to CD79b and minimize effects on normal cells.
Therapeutic Targets Updates:
Learn more about CD22, a cell surface protein that is only expressed on B-cells.
Find out about CD79b, a key component of the B-cell receptor, and its role in malignant B-cell signaling.
Updated Video Narrations:
Biological Pathways: HER signaling: Updated Video
Biological Pathways: Apoptotic pathways: Updated Video
Biological Pathways: MAPK signaling: Updated Video
Biological Pathways: PI3K signaling: Updated Video
Biological Pathways: Angiogenic signaling: Updated Video